Diurnal Group PLC Director Dealings (8088K)

TIDMDNL

RNS Number : 8088K

Diurnal Group PLC

09 May 2022

9 May 2022

Diurnal Group plc

("Diurnal" or the "Company")

Director Dealings

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' dealings undertaken for tax planning purposes:

Richard Ross, Chief Scientific Officer sold 312,000 Ordinary Shares at a price of 13.00 pence per Ordinary Share; his and his wife's (Sarah Ross) ISAs purchased 153,500 Ordinary Shares and 153,500 Ordinary Shares respectively at a price of 13.01 pence per Ordinary Share. Following the transactions, the total beneficial interest of Richard Ross and his connected parties is 2,257,155 Ordinary Shares, representing 1.33% of the total voting rights as at 9 May 2022.

Details of the full notifications received by the Company are set out below:

 
     Details of the person discharging managerial responsibilities 
 1    / person closely associated 
a)   Name                             Richard Ross 
     Reason for the notification 
 2 
a)   Position/status                 Chief Scientific Officer 
b)   Initial notification            Initial notification 
      /Amendment 
     Details of the issuer, emission allowance market participant, 
 3    auction platform, auctioneer or auction monitor 
a)   Name                            Diurnal Group plc 
b)   LEI                             213800I2HNUNZN1LDH29 
     Details of the transaction(s): section to be repeated for 
 4    (i) each type of instrument; (ii) each type of transaction; 
      (iii) each date; and (iv) each place where transactions 
      have been conducted 
a)   Description of the              Ordinary shares of 5 pence each in 
      financial instrument,           Diurnal Group plc 
      type of instrument 
 
     Identification code             GB00BDB6Q760 
 
b)   Nature of the transaction       Sale and purchase of ordinary shares 
c)   Price(s) and volume(s) 
                                           Price(s)               Volume(s) 
                                           Sale 13.00p            312,000 
    Purchase 13.01p                                                153,500 
 
d)   Aggregated information 
 
 - Aggregated volume             As above 
 
 - Price 
 
e)   Date of the transaction         9 May 2022 
f)   Place of the transaction        XLON 
 
 
     Details of the person discharging managerial responsibilities 
 1    / person closely associated 
a)   Name                                Sarah Ross 
     Reason for the notification 
 2 
a)   Position/status                    Closely associated person to an Executive 
                                         Director 
b)   Initial notification               Initial notification 
      /Amendment 
     Details of the issuer, emission allowance market participant, 
 3    auction platform, auctioneer or auction monitor 
a)   Name                               Diurnal Group plc 
b)   LEI                                213800I2HNUNZN1LDH29 
     Details of the transaction(s): section to be repeated for 
 4    (i) each type of instrument; (ii) each type of transaction; 
      (iii) each date; and (iv) each place where transactions 
      have been conducted 
a)   Description of the                 Ordinary shares of 5 pence each in 
      financial instrument,              Diurnal Group plc 
      type of instrument 
 
     Identification code                GB00BDB6Q760 
 
b)   Nature of the transaction          Purchase of ordinary shares 
c)   Price(s) and volume(s) 
                                         Price(s)                     Volume(s) 
   Purchase 13.01p                                                    153,500 
 
d)   Aggregated information 
 
 - Aggregated volume                As above 
 
 - Price 
 
e)   Date of the transaction            9 May 2022 
f)   Place of the transaction           XLON 
 
 
For further information, please visit www.diurnal.co.uk or 
 contact: 
 
                                                  [phone] 
Diurnal Group plc                                  1000 
Richard Bungay, Interim Chief Executive Officer 
 
Panmure Gordon (UK) Limited (Nominated Adviser    [phone] 
 and Joint Corporate Broker)                       2500 
Corporate Finance: Freddy Crossley, Emma Earl 
Corporate Broking: Rupert Dearden 
 
Stifel Nicolaus Europe Limited (Joint Corporate   [phone] 
 Broker)                                           7600 
Healthcare Investment Banking: Nicholas Moore, 
 Samira Essebiyea, William Palmer-Brown 
Corporate Broking: Nick Adams, Nick Harland 
 
                                                  [phone] 
FTI Consulting (Media and Investor Relations)      1000 
Simon Conway 
Victoria Foster Mitchell 
Alex Davis 
 

Notes to Editors

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFSLETIAIIF

(END) Dow Jones Newswires

May 09, 2022 13:13 ET (17:13 GMT)